<a href="https://community.sciex.com/author/commmunitysuperuser/" target="_self">SCIEX Community</a>

SCIEX Community

Comprehensive Therapeutic Protein Characterization Using One Single Method

Jun 19, 2017 | Biopharma, Blogs | 0 comments

Get to know how CESI-MS will allow you to quickly and accurately characterize protein therapeutics for attributes in a single method by downloading this discovery kit.

The Biologics Characterization and Discovery Kit Includes:

  • Executive Summary
  • Tech Note: A Unified Workflow for Monoclonal Antibody Charge Heterogeneity Purity, and Molecular Weight Analyses
  • Webinar: Biologics Characterization and Discovery by CESI-MS
  • Tech Note: CESI-MS Comparison of Tryptic Digests from Different Monoclonal Antibodies in an Assessment of Biosimilarity
  • Tech Note: Structural Characterization of ADCs by a Combination of Intact, Middle-up, and Bottom-up Approaches using CESI-MS

A Unified Workflow for Monoclonal Antibody Charge Heterogeneity Purity, and Molecular Weight Analyses
Discover how combining the unique separation capabilities of capillary zone electrophoresis (CZE) with the advantages of an MS-based detector provide high-resolution structural information and accurate molecular weight information. Using CESI-MS and stand-alone CE functionality of the CESI 8000 Plus system, researchers demonstrate powerful methods to characterize intact and reduced IgG forms.

CESI-MS Comparison of Tryptic Digests from Different Monoclonal Antibodies in an Assessment of Biosimilarity
Includes a summary of work recently published by the research group LSMIS at the University of Strasbourg. It focuses on how CESI-MS can be used to characterize and compare a marketed reference mAb with other biosimilar candidates. A CESI-MS protocol for biosimilarity studies of mAbs has been developed which highlights 100% amino acid sequence coverage & PTM “hot spot” mapping and ID.

Structural Characterization of Antibody-Drug Conjugates (ADCs) by a Combination of Intact, Middle-up and Bottom-up Approaches using CESI-MS
This tech note also summarizes work recently published by the research group at LSMIS. In this tech note, discover how CESI-MS can be used to characterize a gold standard cysteine-linked ADC, brentuximab vedotin. Want to learn more about highlighting DAR calculation under native conditions; drug distribution, drug location, 100% coverage and PTMs? It’s all here.

Visit our website to learn more about CE instruments >

Why SCIEX partners with experts around the world

Innovation in mass spectrometry does not happen in isolation. Some of the most impactful scientific advances emerge from highly specialized research communities – proteomics experts developing new peptide identification workflows, metabolomics researchers curating spectral databases, toxicologists building compound libraries, and biopharma scientists creating novel characterization methods.

Managing ADC characterization: The challenge of turning complexity into confidence

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

3 reasons ZT Scan DIA is changing the game in metabolomics

For years, metabolomics researchers have faced a frustrating reality: modern high-resolution mass spectrometers can detect tens of thousands of molecular features, yet only a fraction can be confidently identified. The challenge is no longer finding molecules. It is generating the high-quality MS/MS data needed to confidently assign structures and extract meaningful biological insights.

Posted by

Community Manager
Tags
Biopharmabiotherapeutic developmentblazechargecompanycoupledevelopmentjobmachinemassmoneynewnumberpowerproteinrapidsystemtechnologytimevariantwork

0 Comments

Submit a Comment

SCIEX Now™ support network
The destination for all your support needs.
Contact support

The power of precision

Visit Danaher site Danaher
© Copyright 2024 SCIEX

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks). Echo® and Echo® MS + system are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.

Pin It on Pinterest

Share This

Share this post with your network